Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus 11-valent recombinant vaccine - Chengdu Institute of Biological Products/National Vaccine and Serum Institute

Next Previous
Drug Profile

Human papillomavirus 11-valent recombinant vaccine - Chengdu Institute of Biological Products/National Vaccine and Serum Institute

Latest Information Update: 16 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chengdu Institute of Biological Products; National Vaccine & Serum Institute
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Human papillomavirus infections
  • Phase II Cervical cancer

Most Recent Events

  • 13 Feb 2026 Human papillomavirus 11-valent recombinant vaccine is still in phase-III trials for Human papillomavirus infections (In adults, Prevention) in China (NCT05262010)
  • 04 Jun 2022 Phase-III clinical trials in Human papillomavirus infections (Prevention, In adults) in China (IM) (NCT05262010)
  • 08 Mar 2022 National Vaccine and Serum Institute in collaboration with Chengdu Institute of Biological Products plans a phase-III trial in Human papillomavirus infections (Prevention) in China (IM) (NCT05262010)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top